FDA sends 30 warning letters to telehealth firms over compounded GLP-1 marketing

The U.S. Food and Drug Administration on March 3 issued 30 warning letters to telehealth companies for promoting compounded versions of GLP-1 receptor agonists as equivalent to FDA-approved drugs, escalating scrutiny of online weight-loss marketing and raising immediate safety and transparency concerns for patients.

The letters, announced in an FDA news release titled "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP‑1s," say promotional materials on company websites made false or misleading claims about compounded semaglutide and tirzepatide, with a smaller number of letters citing liraglutide. Reuters noted the drugs implicated map to widely known brands: semaglutide is the active ingredient in Novo Nordisk’s Wegovy and Ozempic, tirzepatide is used in Eli Lilly’s Zepbound and Mounjaro, and liraglutide is sold as Saxenda by Novo Nordisk.

The agency's letters flagged so‑called "sameness" claims that implied compounded products are the same as FDA‑approved medicines and called out branding practices that obscured product sourcing by making compounded drugs appear to be manufactured by the telehealth companies themselves. Reuters reported that some firms used proprietary labels that hid where the drugs were really made. Yahoo identified several companies named in its coverage, including Kin Meds, GoodGirlRx, WeightCare and PharmaZee, though the full list of 30 recipients has not been published in the outlets reviewed.

FDA Commissioner Marty Makary signaled a tougher posture. Reuters quoted him saying, "It’s a new era of enforcement," and warning companies should not try to "circumvent FDA’s approval process by mass-marketing compounded drugs." A Yahoo account of the statement included a related line attributed to Makary: "It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action." Yahoo also published an excerpt from a warning letter by FDA Deputy Director of Compliance Matt Lash: "Compounded drug products are not FDA‑approved. Your claims imply that your products have been FDA‑approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded."

Compounded drugs, the FDA and Reuters explained, are customized medicines made when a licensed pharmacist or physician combines, mixes or alters ingredients to meet an individual patient’s needs; they are not subject to the agency’s premarket review for safety, efficacy and quality that FDA‑approved drugs undergo. Regulators say compounders may legally serve narrow clinical needs, such as shortages or unique patient requirements, but they are not permitted to mass market alternatives to approved branded drugs.

Companies cited have 15 working days to respond in writing and outline corrective steps, Reuters and PatientCareOnline reported. The letters form a second enforcement wave: Reuters and Pharmaceuticalcommerce said an earlier round of letters in September 2025 targeted manufacturers and sellers, and Pharmaceuticalcommerce linked the increased activity to an executive order that prompted proactive monitoring of pharmaceutical advertising.

Public health experts warn the pattern raises equity and safety issues. Telehealth and direct‑to‑consumer marketing have rapidly reshaped demand for GLP‑1 therapies, sometimes pushing lower‑income patients toward lower‑cost, potentially unvetted options. Regulators argue transparency about sourcing and approval status is essential to protect patients and preserve trust in prescribing decisions.

The FDA action signals tighter oversight of digital marketing for weight‑loss drugs and will likely force telehealth firms and compounders to clarify sourcing and claims. Journalists and clinicians will be watching whether the agency follows letters with fines, referrals or litigation, and whether it publishes the full list of firms named.